Top Story

Delay for submission of basal insulin peglispro to regulatory agencies announced

March 1, 2015

A delay in the submission of basal insulin peglispro to regulatory agencies has been announced by Eli Lilly and Company, according to a press release.

The delay goes beyond the first quarter of 2015 and includes filing with the FDA and European Medicines Agency.

Website expands hypothyroidism education among Spanish speakers

February 28, 2015
To expand its reach in educating individuals about hypothyroidism, AbbVie has launched the Spanish-language website, according to a news release from…
In the Journals

Urinary adiponectin predicts diabetic nephropathy progression in type 1 diabetes

February 27, 2015
Urinary adiponectin strongly and independently predicted the progression of diabetic nephropathy from macroalbuminuria to end-stage renal disease in patients with type 1…
In the Journals

Vitamin D supplementation benefits middle-aged women with low 25-(OH)D levels

February 27, 2015
Middle-aged women with serum 25-hydroxyvitamin D levels less than 20 ng/mL should use vitamin D supplementation, according to study findings published in The Journal of
In the Journals

Energetic adaptations persist in adolescents with extreme obesity after Roux-en-Y

February 27, 2015
Adolescents with extreme obesity who underwent Roux-en-Y gastric bypass experienced energetic adaptations that favor weight regain, along with changes in insulin…
More News Headlines »
low no

Low- and No-Calorie Sweeteners in Weight Management: What Do You Need to Know?

This activity is supported by an educational grant from the American Beverage Association.

The use of low- and no-calorie sweeteners continues to grow as consumers continue to purchase foods and beverages…
More »
Meeting News Coverage Video
Hatipoglu th

Autologous islet cell transplantation effective for chronic pancreatitis

December 3, 2014
In this video exclusive, Betul Hatipoglu, MD, clinical associate professor of medicine of the Endocrinology &…
More »
Obesity Consults: Volume 2, Number 2 Obesity Forum 2014 Highlights

Obesity Consults: Volume 2, Number 2
Obesity Forum 2014 Highlights

This activity is supported by educational grants from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc; Eisai, Inc.; Novo Nordisk; Vivus, Inc.

Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. Treatment options…
More »
Current Issues
View the Current Issues